8-K: Apogee Therapeutics Enters Manufacturing Agreement with Samsung Biologics for APG777

Apogee Therapeutics has entered into a Master Services Agreement with Samsung Biologics for the manufacturing and supply of APG777, a drug substance for clinical development and potential commercial sale.

Summary

• Apogee Therapeutics has entered into a Master Services Agreement (MSA) with Samsung Biologics for the manufacturing and supply of APG777.
• The MSA is effective as of February 28, 2025, and was formally entered into on March 10, 2025.
• Samsung will manufacture and supply APG777 drug substance for clinical development and potential commercial sale, if approved.
• Apogee is obligated to pay Samsung service fees for each manufactured batch, as well as the costs of materials, testing, and storage, as specified in Project Specific Agreements (PSAs).
• The company also entered into an Initial PSA with Samsung, effective as of February 28, 2025, for the production of clinical batches of APG777 at Samsung's facility in Incheon, South Korea.
• The Initial PSA includes process characterization and validation, and manufacture process performance qualification lots of the Product.
• Apogee must purchase certain minimum quantities of the Product under the Initial PSA.
• A separate PSA will be entered into for the manufacture of commercial supply of the Product, with minimum purchase commitments from 2029 to 2034.
• If Apogee elects not to enter into the PSA for commercial supply, it will incur an exit fee in the high single digit millions.
• The MSA will terminate in February 2035, or when any PSA in effect terminates, and may be extended upon mutual agreement.
• The Initial PSA will terminate in December 2034.
• Either party may terminate the MSA or Initial PSA in the event of an uncured material breach, insolvency, or force majeure event by the other party.
• Samsung will provide assistance with certain technology transfer matters if all applicable PSAs have been terminated, subject to exceptions.
• If Apogee terminates the MSA or Initial PSA without cause, it will generally be responsible for paying the purchase price for its aggregate product commitment for the remainder of the term, less any amounts already paid.

Sentiment

Score: 7

Explanation: The announcement is positive as it secures manufacturing capabilities for Apogee's lead drug candidate. However, the financial commitments and potential exit fees introduce some risk.

Positives

• Apogee secures a reliable manufacturing partner in Samsung Biologics for APG777.
• The agreement covers both clinical and potential commercial supply, ensuring a pathway to market if the drug is approved.
• The MSA provides a long-term framework for the partnership, extending until February 2035.

Negatives

• Apogee faces an exit fee in the high single digit millions if it chooses not to enter into a commercial supply agreement.
• Apogee is committed to minimum purchase quantities, which could pose a financial burden if demand is lower than expected.
• Termination of the agreement without cause could result in significant financial penalties for Apogee.

Risks

• The success of the agreement depends on the successful clinical development and approval of APG777.
• Uncured material breach, insolvency, or force majeure events could lead to termination of the agreement.
• Apogee's financial obligations under the agreement could be substantial, especially if minimum purchase commitments are not met or if the agreement is terminated without cause.

Future Outlook

Apogee Therapeutics anticipates a long-term manufacturing partnership with Samsung Biologics, contingent on the successful development and commercialization of APG777. The company expects to enter into a separate PSA with Samsung for the manufacture of commercial supply of the Product, which will provide for certain minimum purchase commitments for each year from 2029 to 2034.

Management Comments

• The document does not contain direct quotes, but it implies management's confidence in Samsung Biologics as a manufacturing partner for APG777.

Industry Context

This agreement reflects a common trend in the biotechnology industry where companies outsource manufacturing to specialized contract manufacturing organizations (CMOs) like Samsung Biologics to leverage their expertise and infrastructure. This allows Apogee to focus on its core competencies in drug development and commercialization.

Comparison to Industry Standards

• Partnering with Samsung Biologics is a common strategy for biotech companies needing large-scale manufacturing capabilities.
• Other companies like Biogen and Roche have also utilized Samsung Biologics for manufacturing their biologics.
• The structure of the agreement, including minimum purchase commitments and potential exit fees, is typical in such manufacturing partnerships.

Stakeholder Impact

• Shareholders: Securing manufacturing capabilities is generally positive for shareholders.
• Employees: The agreement supports the development and potential commercialization of APG777, which could lead to job creation.
• Customers: If APG777 is approved, the agreement ensures a reliable supply of the drug for patients.

Next Steps

• Apogee will file the full text of the MSA and Initial PSA as exhibits with its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.
• Apogee will need to enter into a separate PSA with Samsung for the manufacture of commercial supply of the Product.
• Apogee will need to meet the minimum purchase commitments outlined in the agreements.

Key Dates